iShares Core MSCI AC Asia ex Japan Index ETF(03010.HK) Falls 0.44%, Turnover HKD 5.8603 Million, Turnover Rate 0.01%
NewTimeSpace News: As of 14:29 on April 22, 2026, iShares Core MSCI AC Asia ex Japan Index ETF(03010.HK) fell 0.44% to HKD 82.280, with an intraday turnover of HKD 5.8603 million and a turnover rate of 0.01%. The ETF has an asset size of HKD 41.971 billion, a total issuance of 509 million units, a net asset value (NAV) of HKD 82.468, a premium of 0.21%, a dividend yield of 0.94%, and a board lot size of 100 shares.
iShares Core MSCI AC Asia ex Japan Index ETF(03010.HK) closely tracks the MSCI AC Asia ex Japan Index, which covers 11 Asia-Pacific markets (excluding Japan), including China, Taiwan, South Korea, India, Hong Kong, and Singapore. The index is primarily focused on information technology, with top ten constituents including regional leaders such as TSMC, Samsung Electronics, Tencent, SK Hynix, and Alibaba.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hong Kong Recently Listed Stocks Daily Report: 51WORLD Leads with 22.25% Gain as Robotics Sector Continues to Diverge - 20261020
- CSOP Hang Seng TECH Index ETF (03033.HK) Falls 1.49% Intraday as Tech Names Slide, Robot Concepts Buck the Trend
- Ping An East-West Select ETF (03477.HK) Falls 1.17% Intraday as Nasdaq Rebounds 1.11%
- HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 1.80% Intraday as Hansoh Signs Roche ADC Deal with US$400 Million Upfront